Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials

• Published in: Research and practice in thrombosis and haemostasis Vol. 8; no. 3; p. 102405
• Main Authors: Jiménez-Yuste, Víctor, Oldenburg, Johannes, Tzeng, Eunice, Lim, Elise, Sanabria, Fabian, Mahlangu, Johnny
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2024; Elsevier
• Subjects: comorbidities; comorbidity; emicizumab; hemophilia A; Original; prophylaxis; emicizumab; hemophilia A; comorbidity; comorbidities; prophylaxis

The treatment of older people with hemophilia A (HA) can be complicated by comorbidities. This post hoc analysis evaluates the efficacy and safety of emicizumab in people with HA aged ≥50 years with cardiovascular (CV) risk factors or HIV and/or hepatitis C virus (HCV) infection. The HAVEN 1 (NCT026...